Is NCT05933499 recruiting in Boston, MA?

Yes, NCT05933499 is currently recruiting participants at its Boston, MA location. This obesity clinical trial is actively enrolling qualified participants.

How do I join the obesity clinical trial in Boston?

To join this clinical trial in Boston, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Boston clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Obesity Clinical Trial in Boston, MA

About This Obesity Study in Boston

In adults with obesity seeking treatment, weight loss would ideally be composed almost exclusively of fat mass. However, loss of muscle mass and bone are unintentional consequences of weight loss, which may have negative effects on health by lessening improvements in glucose and insulin levels, reducing resting metabolic rate, and increasing the risk of falls and fractures. Data in animals and humans suggest that bimagrumab, an investigational new drug for obesity that inhibits the activin type II receptor (ActRII) inhibitor, may help maximize loss of fat mass while maintaining muscle mass when used in combination with a glucagon-like peptide 1 receptor agonist (GLP-1 RA). The investigators hypothesize that in a randomized, placebo-controlled trial of 63 adults with obesity randomized to tirzepatide (GLP-1/GIP RA) + bimagrumab, tirzepatide alone, or bimagrumab alone, the combination of tirzepatide + bimagrumab will result in improvements in muscle, fat, and bone compared to tirzepatide alone or bimagrumab alone when given in addition to a lifestyle intervention for weight loss over 52 weeks.

Sponsor: Massachusetts General Hospital

Who Can Participate

Inclusion Criteria

BMI ≥30 kg/m2 or ≥27kg/m2 with at least one weight-related medical condition

Have a history of at least one self-reported unsuccessful behavioral effort to lose body weight

Have an established primary care provider

Exclusion Criteria

Current or prior history of diabetes mellitus based on self-report, use of diabetes medications, HbA1c ≥6.5%, or fasting glucose ≥126 mg/dL

Any single serum transaminase level (i.e., ALT, AST, alk phos) ≥3x the upper limit of normal (ULN)

Serum lipase and/or amylase levels ≥2x ULN

Serum bilirubin level \>1.6 mg/dL

Chronic kidney disease (e.g., estimated glomerular filtration rate (eGFR) \< 45 mL/min)

Total WBC \<3000/μL, neutrophils \<1500/μL, hemoglobin \<12 g/dL, or platelet count \<100,000/μL

Significant coagulopathy, e.g., PT/INR \>1.5

History of familial hypertriglyceridemia or serum fasting triglyceride \>500 mg/dL

Uncontrolled thyroid disease, defined as abnormal TSH with abnormal fT4

Any chronic active infection (e.g., HIV, hepatitis B or C) or hepatitis C treatment within the previous 6 months

Known history or presence of severe active acute or chronic liver disease (e.g., cirrhosis) or conditions with hepatotoxic potential (e.g., gallbladder or bile duct disease, acute or chronic pancreatitis, exocrine pancreatic insufficiency)

Active clinically significant gastric emptying abnormality or chronic use of a drug(s) that directly affect GI motility

History of calcium oxalate kidney stones

History of clinically significant arrhythmias, unstable angina, myocardial infarction, stroke, coronary artery bypass graft surgery, percutaneous coronary intervention, heart failure, valve disorders or defect, pulmonary hypertension, chronic hypotension (\<100/50), or chronic uncontrolled hypertension (\>160/100)

Tachycardia, defined as heart rate \>100 bpm after 5 minutes resting in a sitting position

History of malignancy of any organ system (other than localized squamous or basal cell carcinoma of the skin), treated or untreated, within the previous 5 years

Confirmed diagnosis of current, significant psychiatric disease (e.g., dementia, Alzheimer's disease, schizophrenia, or bipolar disorder). Individuals with adequately treated depression on stable treatment for at least 3 months are eligible.

Prior history of suicide attempt

PHQ-9 score ≥ 15 at screening

Personal or family history of multiple endocrine neoplasia 2A or 2B or medullary thyroid cancer

Active alcohol, drug, or tobacco abuse. For alcohol, an average weekly alcohol intake that exceeds 14 units per week (males) or 7 units per week (females) \[1 unit = 12 oz or 260 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits\] is exclusionary.

Cannabis/THC use greater than once a week over the past three months and unwilling to abstain from use of cannabis/THC products for the duration of the study

Have obesity induced by other endocrinologic disorders (e.g., Cushing syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., Melanocortin 4 Receptor deficiency or Prader Willi syndrome)

History of weight loss surgery or planned weight loss surgery during the trial period

Use of any anti-obesity medication, nutritional supplement, or over the counter (OTC) product for weight loss within the previous 6 months or during study participation

Any new dietary intervention or exercise regimen for weight loss started within the previous 3 months

Weight instability of \>5kg within the previous 3 months

Weight \> 150kg due to limitations of radiology imaging machines

Use of medications known or suspected to induce weight gain within the previous 3 months or during study participation (e.g., anti-androgens, gonadotropin releasing hormone (GnRH) analogs, some anticonvulsant and psychotropic medications (excluding anti-depressant medication) and oral glucocorticoids)

Use of skeletal muscle anabolic agents within the previous 3 months or during study participation (e.g., hormones such as growth hormone or testosterone, nutritional supplements (other than protein) and over-the-counter products labeled as muscle anabolic agents)

Treatment with glucose-lowering agent(s) within 90 days before screening

History of hypersensitivity to monoclonal antibodies or drugs in the same compound class as the study drugs

History of fragility fracture or BMD T-score ≤ -2.5 in participants \> 50 years old

Use of IV bisphosphonates within the previous 2 years or other osteoporosis medications within the previous 12 months or during study participation

Not able or willing to comply with dietary and lifestyle intervention for weight loss, including history of clinically significant condition that precludes regular walking for exercise or contraindication to following a 500-calorie daily deficit, high protein diet

Women who are pregnant or breastfeeding

Women of child-bearing potential, defined as women physiologically capable of becoming pregnant, unless they are using an intrauterine device (IUD) from at least 3 months before the baseline visit through at least 4 months after the last drug dose and an additional contraceptive (barrier) method from screening through at least 4 months after the last drug dose. Women not of child-bearing potential are defined as individuals who (1) have a congenital anomaly such as Mullerian agenesis, resulting in confirmed infertility, (2) are infertile due to surgical sterilization (defined as documented hysterectomy, bilateral salpingo-oophorectomy, bilateral salpingectomy, or bilateral oophorectomy), or (3) are post-menopausal. The following groups of women are eligible to participate: (a) women who are s/p surgical bilateral oophorectomy or total hysterectomy at least 6 weeks before taking study treatment, (b) women who have an IUD (see additional criteria above), (c) women who are s/p tubal ligation provided that they use an additional barrier form of contraception from screening through at least 4 months after the last drug dose, (d) women who are post-menopausal defined as ≥12 months of spontaneous amenorrhea with appropriate clinical and hormonal profile (e.g., age-appropriate, history of vasomotor symptoms, and/or FSH \>40 IU/L), (e) have a congenital anomaly resulting in confirmed infertility, and (f) do not have a history of sexual activity that could lead to pregnancy (i.e., total abstinence has been and is their preferred lifestyle or same-sex partners only).

For men, morning serum testosterone less than 200 ng/dL

Concurrently enrolled in any other type of medical research judged to be scientifically or medically incompatible with this study

Plans to move out of the study area within 16 months, or be out of the study area for \>4 weeks, continuously

Routine MRI exclusion

Donation or loss of 400 mL or more of blood within past 2 months or plasma donation (\> 250 mL) within past 2 weeks

Major surgery in the trial period

Any disorder, unwillingness, or inability not covered by any of the other exclusion criteria, which in the Investigator's opinion, might jeopardize the subject's safety or compliance with the protocol

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT05933499) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Obesity Treatment Options in Boston, MA

If you're searching for obesity treatment options in Boston, MA, this clinical trial (NCT05933499) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced obesity specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all obesity clinical trials near you to find additional studies recruiting in your area.

Obesity Clinical Trial in Boston, MA

Expert Care in Boston

IRB Approved

No-Cost Care

Apply for This Boston Location

Why Participate?

Simple Process